A collaboration aimed to propel translational research into clinical therapeutics
In January 2022 Stanford University and Deerfield Management, a healthcare investment firm, collaborated to create Porter Alliance for Innovative Medicines to accelerate translational research into clinical therapeutics.
Deerfield has committed up to $130 million and additional scientific and operational support to the collaboration to advance research coming out of Stanford faculty laboratories with a focus on drug prototypes emerging from Stanford’s Innovative Medicines Accelerator (IMA).
The IMA is a key partner in the collaboration as it seeks to accelerate the translation of Stanford research discoveries into new medicines while learning more about human biology.
Deerfield is a healthcare investment management firm committed to advancing healthcare through investment, information and philanthropy. For more information, please visit www.deerfield.com.
Stanford University is dedicated to its founding mission of benefitting society through research and education. Stanford strives to create a sustainable future for all, catalyze discoveries about itself and the world, accelerate the societal impact of its research, and educate students as global citizens. Learn more at stanford.edu.
Timeline for Proposal Submissions
Proposal Sourcing
Porter Alliance Discovery’s Scientific Collaboration Director works with faculty to outline an idea.
Scientific Review
Your proposal will be reviewed by members of our scientific team.
Full Proposal
If your idea is selected for further evaluation, you will be invited to submit a full proposal.
Investment Evaluated
Your proposal will be carefully evaluated for funding by Deerfield’s investment team.
For more information on proposal submissions, please reach out to the Porter Alliance Scientific Collaboration Director, Kimberly Griffin, at kimgriff@stanford.edu.
Have more specific questions?
Find answers to commonly asked questions or submit a specific request.
